Skip to content

    Why do some trial participants stop the assigned treatment?

    Why do some trial participants stop the assigned treatment?

    In a clinical trial, not everyone keeps taking the assigned treatment for the entire study. Someone may have side effects, find the schedule difficult, become pregnant, or make another decision with the research team. Stopping treatment can be important information about how a plan works in practice.

    It also doesn't always mean the person has left the study. A participant may stop the assigned medicine and still agree to follow-up visits. That distinction matters when you read the results.

    Two different kinds of stopping

    Imagine a fictional trial that follows people for one year. A participant stops the assigned medicine after three months because of a side effect but agrees to complete the remaining study visits. The researchers may still collect information about that person's health and experiences, depending on the study plan and consent.

    Another participant withdraws from the study and doesn't provide further follow-up information. The research team has less information about what happens afterward. The two situations shouldn't be treated as identical in a report.

    People can choose whether to participate in research, and their preferences matter. A clear study explanation should tell participants what continuing follow-up involves and whom to contact with questions.

    There are many possible reasons

    A participant might stop because of an adverse effect, lack of benefit, another health issue, a change in circumstances or a personal preference. Practical barriers can matter too: appointments, transportation, work schedules and cost may make a research routine difficult to continue.

    The study may also specify circumstances in which the team advises stopping or changing the assigned treatment. The reason helps readers interpret the result. A table that reports only “discontinued” without further detail can leave an important question unanswered.

    Stopping isn't necessarily a sign that the participant did something wrong. A treatment that is hard to tolerate or a schedule that doesn't fit daily life is part of the practical picture researchers need to understand.

    Why continued follow-up can help

    If participants agree to stay in follow-up after stopping treatment, researchers may learn what happened to the study outcome and whether symptoms changed. That information can help address a question about a treatment strategy that includes the possibility that some people will stop.

    If many people provide no later information, researchers must handle the missing data in their analysis. Different methods rely on different assumptions, and the uncertainty can grow. The report should explain how much information was missing and how it was handled.

    Continuing follow-up is not the same as requiring someone to stay on a treatment they don't want or can't tolerate. The research team should explain the options and respect the participant's decisions.

    Read the stopping numbers in context

    Suppose a fictional trial assigns 100 people to each of two groups. Over one year, 12 people in the first group and seven in the second stop their assigned treatment. Those figures would be 12% and 7% of their respective groups. But the comparison becomes more useful when the report says why people stopped and when.

    For example, the first group might have more stops because of digestive symptoms, while a different number stopped for other reasons. The total alone cannot tell you that breakdown. A report may list adverse events as one category and personal decisions or other circumstances separately. Look for both the number of people and the reason given, rather than assuming every stop has the same explanation.

    Check that the figures cover the same follow-up period and that the denominator is clear. Twelve people out of 100 is different from twelve out of 1,000. Even a higher rate in one group does not explain every individual's experience or automatically prove that the assigned medicine caused every reported problem. This example is invented; it isn't a result for a particular GLP-1 treatment.

    For context, in the randomized portion of the STEP 4 semaglutide trial, 2.4% of the continuation group and 2.2% of the placebo-switch group stopped assigned treatment because of adverse events. The comparison followed a 20-week semaglutide lead-in, so it describes people who reached that stage, not everyone who first enrolled.

    What to look for in a report

    The participant flow diagram or results section may show how many people were assigned to each group, how many stopped treatment, how many were lost to follow-up and how many were included in the analysis. Check both groups rather than looking only at one percentage.

    Useful questions include:

    • Why did participants stop the assigned treatment?
    • Did they continue study follow-up afterward?
    • How much outcome information was missing?
    • What did the primary analysis aim to estimate?
    • Were side effects and discontinuations reported for both groups?

    A higher discontinuation rate can be relevant, but the reason and timing matter. Someone stopping after a planned change is not necessarily the same as someone stopping because of a serious symptom.

    If you're in a trial or considering one

    Ask the study team what to do if the treatment is difficult to tolerate and what options exist for follow-up if you stop. Know whom to contact after hours and how to report symptoms. Don't change a study medicine on your own without contacting the team, except as directed in an emergency plan.

    If you're reading a weight-care trial for a personal decision, discuss the benefits, side effects, discontinuation rates and follow-up with your clinician. A trial average is more informative when you also understand how the treatment fit—or didn't fit—participants' lives.

    Stopping treatment is one part of a study's story. Clear reporting lets readers see what happened without confusing that choice with a person's decision to leave research altogether.